Today's noteworthy downgrades include: Aratana Therapeutics (PETX) downgraded to Hold from Buy at Craig-Hallum... Astoria Financial (AF) downgraded to Neutral from Buy at Guggenheim... Cosan (CZZ) downgraded to Neutral from Buy at BofA/Merrill... Cummins (CMI) downgraded to Hold from Buy at BB&T... DSW (DSW) downgraded to Neutral from Buy at B. Riley... Fibrocell Science (FCSC) downgraded to Neutral from Outperform at Wedbush... Galapagos NV (GLPG) downgraded to Neutral from Outperform at Credit Suisse... Heritage Commerce (HTBK) downgraded to Hold from Buy at Sandler O'Neill... International Flavors (IFF) downgraded to Equal Weight from Overweight at Barclays... MINDBODY (MB) downgraded to Equal Weight from Overweight at Morgan Stanley... MercadoLibre (MELI) downgraded to Sell from Neutral at Citi... Navistar (NAV) downgraded to Neutral from Accumulate at Global Hunter... Premiere Global (PGI) downgraded to Equal Weight from Overweight at Stephens... Qorvo (QRVO) downgraded to Sector Weight from Overweight at Pacific Crest... Snyder's-Lance (LNCE) downgraded to Hold from Buy at BB&T... Stryker (SYK) downgraded on M&A sentiment shift at Needham... TD Ameritrade (AMTD) downgraded to Market Perform from Outperform at Wells Fargo... Telecom Argentina (TEO) downgraded to Sell from Neutral at Goldman... Varian Medical (VAR) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Neutral from Buy at Roth Capital... Vodacom (VDMCY) downgraded to Hold from Buy at Deutsche Bank.

Verastem Oncology "announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. "